公开(公告)号：EP0029765A1

公开(公告)日：1981-06-03

申请号：EP80401571.7

申请日：1980-11-04

申请人： EASTMAN KODAK COMPANY (a New Jersey corporation)

发明人： Goodhue, Charles Thomas ,  Esders, Theodore Walter ,  Masurekar, Prakash Sharatchandra

IPC分类号： C12N9/78 ,  C12Q1/34

CPC分类号： C12N9/78 ,  C12Q1/34 ,  C12R1/20 ,  G01N2333/978 ,  Y10S435/85

摘要： A urease-free creatinine iminohydrolase enzyme composition is obtained from an aerobic soil microorganism. The enzyme preferably has a molecular weight of from 250,000 to 300,000; a maximum activity at a pH between 7 and 8 as measured at 37°C; a Km of 3 to 5 mM for creatinine as measured at 37°C, pH 7.5; and a specific activity for creatinine of at least 1.0 unit per milligram of protein in the composition as measured at 37°C, pH 7.5. The preferred enzyme composition is derived from the aerobic soil microorganism ATCC 31,546. Assay methods, compositions, and elements containing the urease-free creatinine iminohydrolase for the determination of creatinine in an aqueous liquid are also disclosed.

公开(公告)号：EP3186387B1

公开(公告)日：2018-10-17

申请号：EP15774495.4

申请日：2015-08-25

申请人： Univerzita Palackého v Olomouci ,  Ustav organicke chemie a biochemie AV CR, v.v.i. ,  Institute of Applied Biotechnologies, A.S.

发明人： KOBERNA, Karel ,  LIGASOVA, Anna ,  ROSENBERG, Ivan ,  LIBOSKA, Radek ,  PAV, Ondrej ,  KVAPIL, Petr ,  FISER, Josef

IPC分类号： C12Q1/34

CPC分类号： C12Q1/34 ,  G01N2333/978

公开(公告)号：EP3132031A4

公开(公告)日：2017-10-18

申请号：EP15780061

申请日：2015-04-17

申请人： UNIV GEORGIA ,  GLYCOSENSORS AND DIAGNOSTICS LLC

发明人： SAMLI KAUSAR N ,  WOODS ROBERT J ,  YANG LORETTA

IPC分类号： C12N9/24 ,  C07K1/14 ,  C12N9/80 ,  C12N15/56 ,  G01N33/68

CPC分类号： C12N9/80 ,  C07K1/14 ,  C12Y305/01052 ,  G01N33/6803 ,  G01N2333/978 ,  G01N2400/00 ,  G01N2440/38

摘要： The carbohydrate processing enzyme PNGase F was catalytically inactivated through mutation. Additional mutations yielded a catalytically inactive carbohydrate-binding protein with lectin-like properties including high affinity and specificity N-linked glycans, O-linked glycans, or both.

公开(公告)号：EP2585613A1

公开(公告)日：2013-05-01

申请号：EP11727197.3

申请日：2011-06-24

申请人： Biocortech

发明人： WEISSMANN, Dinah ,  PUJOL, Jean-François ,  CAVAREC, Laurent ,  VINCENT, Laurent

IPC分类号： C12Q1/68 ,  G01N33/50

CPC分类号： C12Q1/6883 ,  C12Q1/34 ,  C12Q2600/106 ,  C12Q2600/136 ,  C12Q2600/142 ,  C12Q2600/158 ,  G01N33/5023 ,  G01N2333/978 ,  G01N2800/28 ,  G01N2800/2821 ,  G01N2800/2857 ,  G01N2800/30 ,  G01N2800/302 ,  G01N2800/303 ,  G01N2800/304

摘要： The present invention relates to the use of the editing profile of PDE8A pre-mRNA as a specific bio marker of ADARs activities in evolved primate, particularly in Human tissues. The present invention also relates to an in vitro method for predicting in Human an alteration of the mechanism of the ADARs catalysed pre-mRNA editing of target genes, by analysing the PDE8A pre-mRNA editing profile in a peripheral tissue sample containing cells expressing said PDE8A pre-mRNA, such as blood sample. The present invention is also directed to an in vitro method for the screening of potential therapeutic compound and to predict and assess therapeutic efficacy and/or efficiency or to diagnose potential severe brain or peripheral drug side effects implementing said PDE8A pre-mRNA editing profile as specific biomarker. The present invention is further directed to a method for determining the PDE8A pre-mRNA editing profile in Human, particularly by capillary electrophoresis single-strand conformation polymorphism (CE-SSCP) method after amplification by a nested PCR. Finally the invention relates to particular nucleic acid primers implemented in said nested PCR and kit comprising such sets of primers and human cells capable of expressing PDE8A and ADARs.

公开(公告)号：EP1825261B1

公开(公告)日：2011-07-20

申请号：EP05853035.3

申请日：2005-12-01

申请人： Children's Hospital & Research Center at Oakland ,  THE CLEVELAND CLINIC FOUNDATION

发明人： MORRIS, Claudia, R. ,  HAZEN, Stanley, L.

IPC分类号： G01N33/68

CPC分类号： G01N33/6812 ,  G01N2333/978 ,  G01N2800/12 ,  G01N2800/122 ,  G01N2800/22 ,  G01N2800/224 ,  G01N2800/32 ,  Y10T436/106664 ,  Y10T436/171538 ,  Y10T436/177692

公开(公告)号：EP2104516A4

公开(公告)日：2011-01-05

申请号：EP07874248

申请日：2007-11-01

申请人： UNIV ROCHESTER

发明人： SMITH HAROLD C ,  WEDEKIND JOSEPH E ,  BENNETT RYAN PATRICK

IPC分类号： A61K48/00

CPC分类号： C12N9/78 ,  A61L2/0082 ,  A61L2/16 ,  C07K2299/00 ,  C12N2740/16011 ,  C12Q1/10 ,  C12Y305/04005 ,  G01N33/50 ,  G01N33/56983 ,  G01N2333/16 ,  G01N2333/978 ,  G01N2500/02

公开(公告)号：EP2056827A1

公开(公告)日：2009-05-13

申请号：EP07870201.6

申请日：2007-08-07

申请人： Universitätsklinikum Freiburg

发明人： BAUER, Georg

IPC分类号： A61K31/496 ,  A61K31/4196 ,  A61K31/415 ,  A61K31/4174 ,  A61P35/00 ,  C12Q1/00 ,  G01N33/50

CPC分类号： G01N33/5011 ,  A61K31/19 ,  A61K31/195 ,  A61K31/415 ,  A61K31/4174 ,  A61K31/4196 ,  A61K31/496 ,  C12Q1/30 ,  G01N2333/908 ,  G01N2333/978 ,  G01N2510/00 ,  A61K2300/00

摘要： The present invention refers to a method for inducing tumor apoptosis by influencing the ROS (reactive oxygen species) signaling pathway in tumor cells. Increasing the level of ROS leads to the selective inactivation of a tumor cell catalase and subsequently to an apoptosis of these cells. The level of ROS can be increased by increasing the level of nitric oxide through inhibition of the enzymes nitric oxide dioxygenase or arginase. According to the present invention inhibitors of the nitric oxide dioxygenase or arginase can be used for the manufacture of a medicament for the treatment of cancer. The present invention further provides a method for identifying compounds which can be used for the treatment of cancer, wherein the method allows to specifically identify compounds which induce apoptosis through the ROS signaling pathway. The present invention also provides a kit for identifying compounds which induce tumor apoptosis by inactivating a catalase on the tumor cell surface.

公开(公告)号：EP1813606A1

公开(公告)日：2007-08-01

申请号：EP05807084.8

申请日：2005-11-17

申请人： Takeda Pharmaceutical Company Limited

发明人： MATSUMOTO, Takahiro, TAKEDA PHARMA. CO. LTD. ,  KORI, Masakuni, TAKEDA PHARMA. CO. LTD. ,  MIYAZAKI, Junichi, TAKEDA PHARMA. CO. LTD. ,  KIYOTA, Yoshihiro, TAKEDA PHARMA. CO. LTD.

IPC分类号： C07D261/00

CPC分类号： C12Q1/34 ,  A61K31/495 ,  C07D261/20 ,  C07D285/08 ,  C07D413/12 ,  C07D413/14 ,  C07D417/04 ,  C07D417/12 ,  C07D417/14 ,  G01N33/6896 ,  G01N2333/978 ,  G01N2500/00 ,  G01N2800/28

摘要： There is provided a FAAH inhibitor and a prophylactic or therapeutic agent for cerebrovascular disorders or sleep disorders comprising it. The prophylactic or therapeutic agent comprises a compound of the formula (I 0 ):

wherein Z is oxygen or sulfur; R 1 is aryl which may be substituted, or a heterocyclic group which may be substituted; R 1a is a hydrogen atom, a hydrocarbon group which may be substituted, hydroxyl, etc.; R 2 is piperidin-1,4-diyl which may be substituted, or piperazin-1,4-diyl which may be substituted; R 3 is a group formed by eliminating two hydrogen atoms from a 5-membered aromatic heterocyclic group having 1 to 3 heteroatoms selected from nitrogen, oxygen and sulfur, which may be further substituted, -CO-, etc.; and R 4 is a hydrocarbon group which may be substituted, or a heterocyclic group which may be substituted; or a salt thereof.

摘要翻译： 提供了FAAH抑制剂和包含其的脑血管障碍或睡眠障碍的预防或治疗剂。 预防或治疗剂包括式（I 0）的化合物：其中Z是氧或硫; R 1为可被取代的芳基，或可被取代的杂环基; R 1a是氢原子，可被取代的烃基，羟基等; R 2可以被取代的哌啶-1,4-二基或可被取代的哌嗪-1,4-二基; R 3是通过从具有1至3个选自氮，氧和硫的杂原子的5元芳族杂环基中除去两个氢原子而形成的基团，其可进一步被-CO-等取代; R 4为可被取代的烃基，或可被取代的杂环基; 或其盐。

公开(公告)号：EP1599217A4

公开(公告)日：2006-11-02

申请号：EP03774504

申请日：2003-09-29

申请人： PHOENIX PHARMACOLOGICS INC

发明人： CLARK MIKE A

IPC分类号： A61K38/44 ,  A61K38/45 ,  A61K38/50 ,  A61K45/06 ,  A61K47/48 ,  A61P31/14 ,  C12N9/06 ,  C12N9/96 ,  C12N11/06 ,  C12N11/08 ,  C12Q1/18

CPC分类号： C12Q1/18 ,  A61K38/50 ,  A61K45/06 ,  A61K47/60 ,  G01N2333/978 ,  A61K2300/00

摘要： The present invention is directed to methods of modulating viral replication in vivo comprising administering to an individual a therapeutically or prophylactically effective amount of a composition comprising arginine deiminase modified with polyethylene glycol, to methods of concurrently modulating viral replication and treating cancer, and to methods of modulating nitric oxide levels in a patient, among others.

公开(公告)号：EP1670895A2

公开(公告)日：2006-06-21

申请号：EP04788573.6

申请日：2004-09-03

申请人： UNIVERSITY OF ROCHESTER

发明人： SMITH, Harold, C. ,  WEDEKIND, Joseph, E. ,  SOWDEN, Mark, P. ,  DEWHURST, Stephen ,  KIM, Baek

IPC分类号： C12N1/00

CPC分类号： G01N33/56988 ,  C12Y305/04005 ,  C12Y305/04014 ,  G01N2333/16 ,  G01N2333/978 ,  G01N2500/04

摘要： Disclosed are compounds that enhance RNA or DNA editing, as well as methods of using, identifying, and making such compounds. These compounds include Vif antagonists and cytidine deaminase inhibitors.